RITONAVIR by Hikma is 12. Approved for combination with other antiretroviral agents for the treatment of hiv-1 infection (). First approved in 2020.
Drug data last refreshed 1h ago
12.1 Mechanism of Action Ritonavir is an antiretroviral drug [see ] . 12.2 Pharmacodynamics Cardiac Electrophysiology QTcF interval was evaluated in a randomized, placebo and active (moxifloxacin 400 mg once-daily) controlled crossover study in 45 healthy adults, with 10 measurements over 12 hours…
Worked on RITONAVIR at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3
Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV
A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children
A Study of Ritonavir/Indinavir Combination in HIV-Infected Patients
Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults